Neurology Grand Rounds

“Tuberous Sclerosis Complex: A Clinical Update and New Treatment Options”

James Wheless, MD
Professor and LeBonheur Chair of Pediatric Neurology
University of Tennessee Health Science Center
Director, LeBonheur Comprehensive Epilepsy Program and Neuroscience Institute
St. Jude’s Children’s Research Hospital

Sponsored by Epilepsy Information Services

Tuesday, October 28
12:15-1:15
Sticht Center Auditorium

Sponsorship: This activity is sponsored by Wake Forest School of Medicine.

Accreditation: The Wake Forest School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit: The Wake Forest School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives: At the conclusion of this CME activity, the learner should be better able to:
1. To be familiar with the clinical manifestations of tuberous sclerosis complex.
2. To understand the role of mTOR inhibitors in the treatment of tuberous sclerosis complex
3. To be aware of the role of epilepsy surgery in the treatment of tuberous sclerosis complex and intractable seizures

Disclosure:
Planning Committee: Dr. Kumar discloses Suzanne Collin Foundation (grant/research support), Dr. Pharr discloses Questor and Teva (advisory Boards), Dr. Jane Boggs discloses Upshue-Smith, Neuropace, Sage (grant/research support), Dr. Allison Brashear discloses (Ipsen, Allergan, Merz – research/grant support, Allergan consultant)
No other member of the Planning Committee has anything to disclose.

Speaker: Dr. Wheless discloses (grants) NIH, Shainberg Foundation, GSK, Novartis, Upsher-Smith, Sunovion, Cyberonics, (consultant/speaker bureau) Lundbeck, Questcr, Cyberonics, Pfizer, Eisai, Sunovion, Supernus, Upsher-Smith (please see disclosure form on table)